JP2018534932A5 - - Google Patents

Download PDF

Info

Publication number
JP2018534932A5
JP2018534932A5 JP2018522662A JP2018522662A JP2018534932A5 JP 2018534932 A5 JP2018534932 A5 JP 2018534932A5 JP 2018522662 A JP2018522662 A JP 2018522662A JP 2018522662 A JP2018522662 A JP 2018522662A JP 2018534932 A5 JP2018534932 A5 JP 2018534932A5
Authority
JP
Japan
Prior art keywords
polypeptide
activity
ion
small molecule
assay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018522662A
Other languages
English (en)
Japanese (ja)
Other versions
JP7064769B2 (ja
JP2018534932A (ja
Filing date
Publication date
Priority claimed from PCT/US2016/019242 external-priority patent/WO2016138071A1/en
Application filed filed Critical
Priority claimed from PCT/US2016/049715 external-priority patent/WO2017078839A1/en
Publication of JP2018534932A publication Critical patent/JP2018534932A/ja
Publication of JP2018534932A5 publication Critical patent/JP2018534932A5/ja
Priority to JP2022068158A priority Critical patent/JP7390748B2/ja
Application granted granted Critical
Publication of JP7064769B2 publication Critical patent/JP7064769B2/ja
Priority to JP2023193435A priority patent/JP2024020382A/ja
Priority to JP2025185767A priority patent/JP2026027333A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018522662A 2015-11-02 2016-08-31 条件的活性型ポリペプチド Active JP7064769B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022068158A JP7390748B2 (ja) 2015-11-02 2022-04-18 条件的活性型ポリペプチド
JP2023193435A JP2024020382A (ja) 2015-11-02 2023-11-14 条件的活性型ポリペプチド
JP2025185767A JP2026027333A (ja) 2015-11-02 2025-11-04 条件的活性型ポリペプチド

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562249907P 2015-11-02 2015-11-02
US62/249,907 2015-11-02
PCT/US2016/019242 WO2016138071A1 (en) 2015-02-24 2016-02-24 Conditionally active biological proteins
USPCT/US2016/019242 2016-02-24
PCT/US2016/049715 WO2017078839A1 (en) 2015-11-02 2016-08-31 Conditionally active polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022068158A Division JP7390748B2 (ja) 2015-11-02 2022-04-18 条件的活性型ポリペプチド

Publications (3)

Publication Number Publication Date
JP2018534932A JP2018534932A (ja) 2018-11-29
JP2018534932A5 true JP2018534932A5 (https=) 2019-10-10
JP7064769B2 JP7064769B2 (ja) 2022-05-11

Family

ID=58662272

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018522662A Active JP7064769B2 (ja) 2015-11-02 2016-08-31 条件的活性型ポリペプチド
JP2022068158A Active JP7390748B2 (ja) 2015-11-02 2022-04-18 条件的活性型ポリペプチド
JP2023193435A Pending JP2024020382A (ja) 2015-11-02 2023-11-14 条件的活性型ポリペプチド
JP2025185767A Pending JP2026027333A (ja) 2015-11-02 2025-11-04 条件的活性型ポリペプチド

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022068158A Active JP7390748B2 (ja) 2015-11-02 2022-04-18 条件的活性型ポリペプチド
JP2023193435A Pending JP2024020382A (ja) 2015-11-02 2023-11-14 条件的活性型ポリペプチド
JP2025185767A Pending JP2026027333A (ja) 2015-11-02 2025-11-04 条件的活性型ポリペプチド

Country Status (10)

Country Link
US (2) US11472876B2 (https=)
EP (1) EP3371349A4 (https=)
JP (4) JP7064769B2 (https=)
KR (2) KR20240150525A (https=)
CN (2) CN115521374B (https=)
AU (2) AU2016350613B2 (https=)
CA (1) CA3003399A1 (https=)
MX (2) MX2018005063A (https=)
RU (1) RU2735023C9 (https=)
WO (1) WO2017078839A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2947605A1 (en) * 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
WO2017078839A1 (en) * 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
US10697972B2 (en) 2016-01-12 2020-06-30 Bioatla, Llc Diagnostics using conditionally active antibodies
EP3403098B1 (en) * 2016-01-12 2021-09-22 BioAtla, Inc. Diagnostics using conditionally active antibodies
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
KR102873209B1 (ko) * 2016-08-31 2025-10-17 바이오아트라, 인코퍼레이티드 조건부 활성 폴리펩티드 및 이를 제조하는 방법
EP3568159A4 (en) 2017-01-11 2020-08-05 Bristol-Myers Squibb Company PSGL-1 ANTAGONISTS AND THEIR USES
SG10202107808SA (en) 2017-01-18 2021-08-30 F1 Oncology Inc Chimeric antigen receptors against axl or ror2 and methods of use thereof
KR102715540B1 (ko) 2017-03-14 2024-10-08 파이브 프라임 테라퓨틱스, 인크. 산성 pH에서 VISTA에 결합하는 항체
BR112020019083A2 (pt) 2018-03-21 2020-12-29 Five Prime Therapeutics, Inc. Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer
IL279399B1 (en) * 2018-06-14 2026-04-01 Bioatla Llc Multispecific antibody templates
BR112021000303A2 (pt) 2018-07-11 2021-04-13 Five Prime Therapeutics, Inc. Anticorpos que se ligam a vista em ph ácido
SG11202100961UA (en) * 2018-08-21 2021-03-30 Bioatla Inc CONDITIONALLY ACTIVE PROTEINS WITH pH SELECTIVITY
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
JP7720785B2 (ja) 2019-04-18 2025-08-08 ブリストル－マイヤーズ スクイブ カンパニー 低ｐＨで結合するために特異性が増強されたイピリムマブバリアント
JP7785023B2 (ja) * 2020-06-15 2025-12-12 サレプタ セラピューティクス， インコーポレイテッド アデノ関連ウイルス抗体及びそのフラグメント
CA3182384A1 (en) * 2020-06-18 2021-12-23 Jay M. Short Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereof
CA3182395A1 (en) * 2020-06-18 2021-12-23 Jay M. Short Conditionally active anti-nectin-4 antibodies
WO2024155457A2 (en) * 2023-01-18 2024-07-25 Harpoon Therapeutics, Inc. Her2 targeting trispecific protein for treatment of cancer
JP2026507181A (ja) * 2023-03-02 2026-02-27 バイオアトラ インコーポレイテッド 条件的活性型抗ＥｐＣＡＭ抗体、抗体断片及びそれを組み込んだ構築物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
ATE241011T1 (de) 1991-02-27 2003-06-15 Micromet Ag Serin-reiche peptidlinker
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
GB9320668D0 (en) 1993-10-07 1993-11-24 Secr Defence Liposomes containing particulare materials
JPH10503371A (ja) 1994-07-29 1998-03-31 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 新規化合物
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
EP1323346B1 (en) 1995-01-17 2006-06-28 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
AU6330896A (en) 1995-06-07 1996-12-30 Governors Of The University Of Alberta, The A method for eliciting a th1-specific immune response
US6764835B2 (en) 1995-12-07 2004-07-20 Diversa Corporation Saturation mutageneis in directed evolution
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
ES2244169T3 (es) 1998-02-09 2005-12-01 Bracco International B.V. Suministro direccionado de medios biologicamente activos.
CZ302070B6 (cs) 1998-04-21 2010-09-29 Micromet Ag Jednoretezcový multifunkcní polypeptid, polynukleotid, vektor obsahující tento polynukleotid, bunka transfekovaná tímto polynukleotidem, prostredek obsahující tento polypeptid, polynukleotid nebo vektor a jejich použití a zpusob identifikace aktiváto
US6573050B1 (en) * 1999-10-29 2003-06-03 Sunnybrook & Women's College Health Sciences Centre Treatment, diagnosis and evaluation of anti-cancer therapy resistance in melanoma
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
US20020028178A1 (en) 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
SG136804A1 (en) 2000-07-12 2007-11-29 Idec Pharma Corp Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
US20040136908A1 (en) 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
JP4199545B2 (ja) * 2001-04-27 2008-12-17 ビボキシド オサケユイチア 軟組織付着の改善方法、および移植片作製のための該方法の使用
DE50202507D1 (de) 2001-10-17 2005-04-21 Schneider Gmbh & Co Kg Vorrichtung und verfahren zur komplettbearbeitung von zweiseitig optisch aktiven linsen
AU2003256266A1 (en) * 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
US20040064050A1 (en) 2002-09-20 2004-04-01 Jun Liu System and method for screening tissue
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
US20050260711A1 (en) * 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
KR20070057839A (ko) 2004-08-19 2007-06-07 제넨테크, 인크. 변경된 이펙터 기능을 갖는 폴리펩티드 변이체
WO2009021232A2 (en) 2007-08-09 2009-02-12 Massachusetts Institute Of Technology High-throughput, whole-animal screening system
JP2010068746A (ja) * 2008-09-18 2010-04-02 Chiba Univ 抗腫瘍効果を有する化合物の同定方法
US20100189651A1 (en) 2009-01-12 2010-07-29 Cytomx Therapeutics, Llc Modified antibody compositions, methods of making and using thereof
US9464284B2 (en) * 2009-03-09 2016-10-11 Bioatla, Llc Mirac proteins
ES2652340T3 (es) 2009-07-17 2018-02-01 Bioatla Llc Selección y evolución simultáneas e integradas de rendimiento y expresión de proteínas humanas en huéspedes de producción
US20110143960A1 (en) 2009-12-10 2011-06-16 Labarbera Daniel V 3d-models for high-throughput screening drug discovery and development
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
CA2810668A1 (en) * 2010-09-08 2012-03-15 Halozyme, Inc. Methods for assessing and identifying or evolving conditionally active therapeutic proteins
WO2013040445A1 (en) 2011-09-15 2013-03-21 Whitehead Institute For Biomedical Research Arrays for cell-based screening and uses thereof
RU2732151C2 (ru) 2011-09-30 2020-09-11 Чугаи Сейяку Кабусики Кайся Библиотека зависимых от концентрации ионов связывающих молекул
KR101721678B1 (ko) 2012-03-08 2017-03-31 할로자임, 아이엔씨 조건부 활성 항-표피 성장 인자 수용체 항체 및 이의 사용 방법
US20140206596A1 (en) * 2013-01-18 2014-07-24 University Of Southern California Design of pH-Sensitive Oligopeptide Complexes For Drug Release Under Mildly Acidic Conditions
CA2947605A1 (en) 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
WO2017078839A1 (en) 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
KR102873209B1 (ko) * 2016-08-31 2025-10-17 바이오아트라, 인코퍼레이티드 조건부 활성 폴리펩티드 및 이를 제조하는 방법

Similar Documents

Publication Publication Date Title
JP2018534932A5 (https=)
RU2018115781A (ru) Условно активные полипептиды
AR112639A1 (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y métodos de uso de anticuerpos anti-cd39
JP2020536488A5 (https=)
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
JP2018521638A5 (https=)
JP2014518883A5 (https=)
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
JP2016196468A5 (https=)
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
CL2008003004A1 (es) Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos.
JP7619939B2 (ja) 原発性免疫不全症、シスチン症、及びウィルソン病に関する新生児スクリーニング
Lu et al. Frontier of therapeutic antibody discovery: The challenges and how to face them
WO2019235915A8 (en) Methods and means for attracting immune effector cells to tumor cells
US11970543B2 (en) Anti-CD39 antibodies and use thereof
JP2021517459A5 (https=)
IL273578B1 (en) Antibodies targeting pdl1 and methods of use thereof
WO2024086617A3 (en) Ph-dependent anti-cd3 antibodies and methods relating thereto
EP3103810A3 (en) Modified variable domain molecules and methods for producing and using them
WO2021112676A3 (en) Methods and means for attracting immune effector cells to tumor cells
WO2020225799A3 (en) A method of decreasing concentration of tau (τ) protein and/or phosphorylated tau (τ) protein
AR095499A1 (es) ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b
PE20240224A1 (es) Anticuerpo biespecifico anti-tspan8/anti-cd3 y anticuerpo anti-tspan8
JP2018537117A5 (https=)
RU2021128024A (ru) Способы культивирования клеток